Clinical Trials on Castrate-resistant Prostate Cancer (CRPC) in Portugal

Total 39 results

Merck Sharp & Dohme LLC
Orion Corporation, Orion Pharma

Recruiting

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Prostatic Neoplasms | Metastatic Castration-resistant Prostate Cancer (mCRPC)

Australia, Germany, United States, Puerto Rico, Israel, Korea, Republic of, Taiwan, China, Costa Rica, Guatemala, Spain, France, Hong Kong, Portugal, Romania, Chile, Czechia, Hungary, Italy, Sweden, Turkey, United Kingdom, Estonia, Ir... and more
Fundacao Champalimaud

Unknown

Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer

Metastatic Prostate Cancer | Prostate Adenocarcinoma

Portugal
Fundacao Champalimaud

Completed

Phase II Study of Ultra-high-dose Hypofractionated vs. Single-dose Image-Guided Radiotherapy for Prostate Cancer (PROSINT)

PROSTATE CANCER

Portugal
Fundacao Champalimaud

Recruiting

Phase II Study of Single-Dose Image-Guided Radiotherapy (SDRT) for Prostate Cancer (PROSINT II)

Prostate Cancer

Portugal
SOTIO a.s.

Completed

Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer (VIABLE)

Metastatic Castration-resistant Prostate Cancer

United States, Spain, United Kingdom, Germany, Serbia, Portugal, Lithuania, Slovakia, Hungary, Netherlands, Croatia, France, Czechia, Poland, Austria, Belarus, Belgium, Bulgaria, Denmark, Italy, Latvia, Sweden
Hospital de Santa Maria, Portugal

Completed

A Prospective Randomized Trial of Prostate Biopsy Protocols Comparing the Vienna Nomogram and a Standard 10-core Biopsy Scheme

Prostate Cancer

Portugal
Astellas Pharma Europe Ltd.
Medivation, Inc.

Completed

European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) (PREMISE)

Metastatic Castration Resistant Prostate Cancer

Czechia, Netherlands, Denmark, Italy, Austria, Belgium, Bulgaria, France, Germany, Greece, Hungary, Ireland, Portugal, Slovenia, Spain, United Kingdom
Bayer
Orion Corporation, Orion Pharma

Completed

Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer (ARAMIS)

Prostate Cancer Non-Metastatic | Castration-Resistant

Belgium, France, Poland, Spain, Canada, United States, Estonia, Portugal, Taiwan, Japan, Russian Federation, Finland, Germany, Austria, Czechia, Hungary, Australia, Brazil, South Africa, Latvia, Italy, United Kingdom, Turkey, Serbia, Ro... and more
BioProtect

Completed

Retrospective Evaluation of Commercial Spacers in Prostate Cancer Patients (CLP-10095)

Prostate Cancer

Poland, Portugal
Universidade do Porto
Horizon 2020 - European Commission

Recruiting

Testing an e-Health Intervention for Prostate Cancer Survivors' Mental and Sexual Health

Prostate Cancer

Portugal
Bayer

Active, not recruiting

Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer (REASSURE)

Metastatic Castration-resistant Prostate Cancer

United States, Austria, Czechia, Israel, Italy, Germany, United Kingdom, France, Mexico, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Denmark, Sweden, Argentina, Portugal
Associacao de Investigacao de Cuidados de Suporte...
Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.; University Institute... and other collaborators

Unknown

Walking Football as a Supportive Medicine for Patients With Prostate Cancer

Prostate Cancer | Androgen Deprivation Therapy

Portugal
BioProtect

Recruiting

Post Marketing Clinical Follow Up of the BioProtect Balloon Implant System (CLP-10441)

Prostate Cancer

Ireland, Israel, Netherlands, Poland, Portugal
European Organisation for Research and Treatment...

Completed

Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases

Prostate Cancer | Metastatic Cancer

Netherlands, Denmark, Belgium, Poland, Switzerland, United Kingdom, Italy, Russian Federation, Portugal
BioProtect

Completed

ProSpace™ Balloon System Pivotal Study BP-007

Prostate Cancer

United States, Israel, United Kingdom, Netherlands, Poland, Portugal
Janssen Research & Development, LLC

Active, not recruiting

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE)

Castration-Resistant Prostatic Cancer

United States, China, Italy, Korea, Republic of, Taiwan, Australia, Sweden, Belgium, Canada, France, Hungary, Israel, Malaysia, Russian Federation, Portugal, Germany, Bulgaria, Spain, Netherlands, Turkey, United Kingdom, Ukraine, Po... and more
Sanofi

Completed

Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

Prostate Cancer Metastatic

Australia, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czech Republic, Denmark, Finland, Hungary, India, Ireland, Italy, Kazakhstan, Luxembourg, Malaysia, Mexico, Philippines, Poland, Portugal, Romania, Serbia, Singapo... and more
European Organisation for Research and Treatment...

Completed

Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate

Prostate Cancer

Belgium, Poland, Italy, Austria, France, Denmark, Netherlands, United Kingdom, Israel, Spain, Portugal
AstraZeneca

Completed

(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer (Capri)

Non-Metastatic Prostate Cancer

Czech Republic, Italy, South Africa, United Kingdom, Germany, Poland, Netherlands, Austria, Belgium, Hungary, Israel, Portugal, Mexico, Spain, Australia, Ireland
Ferring Pharmaceuticals

Completed

Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients

Prostate Cancer

Belgium, Italy, Sweden, Portugal, Denmark, Finland, Norway, Turkey
Fundacao Champalimaud

Unknown

Stereotactic Hypofractionated Accelerated Radiotherapy Post-Prostatectomy (SHARP)

SBRT | Adjuvant Radiotherapy | Prostate Cancer Adenocarcinoma | Salvage Radiotherapy | IGRT | Urethral Sparing

Portugal
Exelixis
Takeda; Roche-Genentech

Active, not recruiting

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02)

Metastatic Prostate Cancer | Prostate Adenocarcinoma

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Portugal, Russian Federation, Singapore, Spain, ... and more
AstraZeneca

Completed

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer (ENTHUSE M1C)

Prostate Cancer

Sweden, United States, Brazil, France, Peru, Spain, United Kingdom, Germany, Poland, Romania, Finland, Canada, Argentina, Australia, South Africa, Czech Republic, India, Netherlands, Italy, Switzerland, Korea, Republic of, Hungary, ... and more
Ferring Pharmaceuticals

Completed

A Long Term Safety Study of Degarelix in Patients With Prostate Cancer

Prostate Cancer

Spain, France, Belgium, Italy, Sweden, Portugal, Turkey
GlaxoSmithKline

Completed

"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk (REDUCE)

Neoplasms, Prostate

United States, Australia, France, Germany, Spain, Bulgaria, Estonia, Italy, Poland, Netherlands, Belgium, United Kingdom, Canada, Denmark, Ukraine, Finland, Latvia, Russian Federation, Greece, Slovenia, Brazil, Mexico, Slovakia, Japan, Puerto... and more
Hoffmann-La Roche

Active, not recruiting

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer (IPATential150)

Metastatic Prostate Cancer

United States, Belgium, France, United Kingdom, Canada, Korea, Republic of, China, Denmark, Greece, Ireland, Portugal, Spain, Italy, Brazil, Mexico, Australia, Thailand, Japan, Costa Rica, Israel, Russian Federation, Austria, Hungary, Norwa... and more
Ipsen

Completed

Study to Evaluate the Presence of Lower Urinary Tract Symptoms (LUTS) in Prostate Cancer Patients Scheduled to Receive Luteinizing Hormone Releasing Hormone (LHRH) Analogues (ANALUTS)

Prostate Cancer

Spain, Portugal
Ferring Pharmaceuticals

Completed

A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON

Prostate Cancer

United Kingdom, Netherlands, Ireland, Greece, France, Belgium, Denmark, Norway, Italy, Slovakia, Switzerland, Portugal, Finland, Hungary, Germany
Janssen Pharmaceutica N.V., Belgium

Completed

A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical Care

Prostate Cancer

France, Poland, United Kingdom, Belgium, Germany, Spain, Israel, Portugal, Slovenia, Turkey, Sweden, Austria, Russian Federation, Luxembourg, Switzerland
Sanofi

Completed

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer (FIRSTANA)

Prostate Cancer

Australia, Portugal, Spain, Peru, Sweden, Romania, Russian Federation, Belarus, Israel, France, Italy, Denmark, Turkey, Germany, United States, Brazil, Canada, China, Czechia, Finland, Japan, Mexico, Poland, Taiwan, Ukraine
AstraZeneca

Completed

Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease

Breast Cancer | Bone Neoplasms | Prostate Cancer

United States, United Kingdom, Sweden, Norway, Canada, Portugal, Denmark, Spain
Millennium Pharmaceuticals, Inc.

Completed

Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer

United States, France, Ukraine, United Kingdom, Belgium, Germany, Taiwan, Spain, Belarus, Israel, Portugal, Bulgaria, Romania, South Africa, Japan, Switzerland, Canada, Australia, Netherlands, Greece, Chile, New Zealand, Peru, Singapore, Russian Federation and more
Janssen Research & Development, LLC

Active, not recruiting

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (AMPLITUDE)

Metastatic Castration-sensitive Prostate Cancer

United States, Italy, China, Korea, Republic of, Canada, Australia, United Kingdom, Hungary, France, Taiwan, Thailand, Germany, Malaysia, Denmark, Russian Federation, New Zealand, Ukraine, Bulgaria, Israel, Spain, Turkey, Sweden, Cz... and more
Bayer

Recruiting

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP)

Biochemically Recurrent Prostate Cancer

Austria, Spain, United States, Australia, Brazil, France, Germany, Taiwan, Denmark, China, Netherlands, Portugal, Japan, Canada, Finland, Italy, Hungary, United Kingdom, Poland, Israel, New Zealand, Sweden, Belgium, Czechia
AstraZeneca

Terminated

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer (ENTHUSE M0)

Prostate Cancer

Sweden, United States, Brazil, Czech Republic, France, Italy, Peru, Russian Federation, Spain, Turkey, United Kingdom, Germany, China, Hungary, Latvia, Poland, Romania, Japan, Finland, Norway, Canada, South Africa, Argentina, Australia, Belgiu... and more
Amgen

Recruiting

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer

Japan, United States, Korea, Republic of, Taiwan, Australia, Spain, Germany, Switzerland, Portugal, China
AstraZeneca

Completed

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases (ENTHUSE M1)

Prostate Cancer

Sweden, United States, Brazil, Czech Republic, France, Russian Federation, United Kingdom, Germany, China, Hungary, Poland, Finland, Netherlands, Mexico, Hong Kong, Australia, Belgium, Canada, Denmark, Portugal, South Africa, Korea... and more
RECORDATI GROUP

Active, not recruiting

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Prostate Cancer | Neuroendocrine Tumors | Acromegaly | Cushing's Disease | Dumping Syndrome | Pituitary Tumors | Ectopic ACTH Secreting (EAS) Tumors | Melanoma Negative for bRAF | Melanoma Negative for nRAS

Belgium, Brazil, Bulgaria, Canada, France, Germany, Italy, Japan, Korea, Republic of, Thailand, Turkey, United States, Argentina, Greece, Hungary, India, Israel, Malaysia, Mexico, Netherlands, Peru, Poland, Portugal, Romania, Russian Federation and more
Actuate Therapeutics Inc.

Active, not recruiting

9-ING-41 in Patients With Advanced Cancers

Sarcoma | Cancer | Breast Neoplasms | Neoplasm Metastasis | Pancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Bone Cancer | Malignant Glioma | Bone Metastases | Pancreas Cancer | Renal Cancer | Refractory Non-Hodgkin Lymphoma | Bone Neoplasm | Neoplasm, Breast | Refractory Cancer | Refractory Neoplasm | Resistant... and other conditions

United States, Belgium, Canada, Spain, France, Netherlands, Portugal

Clinical Trials on Castrate-resistant Prostate Cancer (CRPC) in Portugal

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations